Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer

doi:10.3748/wjg.v22.i23.5332

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 23

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11991)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-1) series.

Item

Count

PDF

845

WORD

299

HTML

6383

Figures (1-3)

529

Tables (1-1)

256

Sum=8312

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

397

Download

636

Sum=1033

Publishing Process of This Article

Item

Count

Browse

1137

Download

1509

Sum=2646

Jun 21, 2016 (publication date) through Nov 5, 2024

Times Cited of This Article

Times Cited (18)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Jun 21, 2016; 22(23): 5332-5341
Published online Jun 21, 2016. doi: 10.3748/wjg.v22.i23.5332

Open in New Tab Full Size Figure Download Figure

Figure 1 Development of cytotoxic and targeted agents for the treatment of colorectal cancer. ¹KRAS wide-type patients. CRC: Colorectal cancer; 5-FU: 5-fluorouracil; LV: Leucovorin; IFL: Irinotecan + 5-fluorouracil + leucovorin; FOLFOXIRI: Leucovorin + 5-fluorouracil + oxaliplatin + irinotecan.

Open in New Tab Full Size Figure Download Figure

Figure 2 Toxicity of cetuximab combined with oxaliplatin-based chemotherapy summarized from the published clinical trials. FOLFOX: Leucovorin + 5-fluorouracil + oxaliplatin; CAPOX: Capecitabine + oxaliplatin; CAPIRI: Capecitabine + irinotecan; FLOX: 5-fluorouracil/leucovorin bolus + oxaliplatin.

Open in New Tab Full Size Figure Download Figure

Figure 3 Toxicity of cetuximab combined with irinotecan-based chemotherapy summarized from the published clinical trials. FOLFIRI: Leucovorin + 5-fluorouracil + irinotecan; CAPIRI: Capecitabine + irinotecan.

Citation: Wen F, Li Q. Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer. World J Gastroenterol 2016; 22(23): 5332-5341
URL: https://www.wjgnet.com/1007-9327/full/v22/i23/5332.htm
DOI: https://dx.doi.org/10.3748/wjg.v22.i23.5332